Table 1 Baseline patient, tumor, and treatment characteristics
Characteristics | All (n = 21) |
|---|---|
No. of patients (%) | |
Age, years | |
Median (range) | 51 (36–72) |
Race | |
White | 18 (86%) |
Black or African-American | 1 (5%) |
Asian | 1 (5%) |
Other | 1 (5%) |
ECOG PS at baseline | |
0 | 9 (43%) |
1 | 11 (52%) |
2 | 1 (5%) |
Disease-free interval | |
<2 years | 16 (76%) |
>2 years | 4 (19%) |
Stage IV disease at diagnosis | 1 (5%) |
Inflammatory breast cancera | 1 (5%) |
Adjuvant or neoadjuvant chemotherapy | |
Adjuvant or neoadjuvant anthracycline | 17 (81%) |
Adjuvant or neoadjuvant taxane | 16 (76%) |
Lines of chemotherapy for metastasis or recurrence | |
Median (range) | 2 (1–8) |
None | 0 (0%) |
1 line | 6 (29%) |
2 lines | 5 (24%) |
3+ lines | 10 (48%) |
Prior chemotherapy for metastasis or recurrence | |
Capecitabine | 9 (43%) |
Platinum salt | 12 (57%) |
Eribulin | 5 (24%) |
